Abstracts Archive - Page 1859 of 2616 - ACR Meeting Abstracts

Abstract Number: 2919 • 2015 ACR/ARHP Annual Meeting
Effect of Thrombotic Microangiopathy on Clinical Outcomes in LUPUS Nephritis
Krishan Gupta¹, Manish Rathi², Navin Pattanashetti³, Ritambhra Nada⁴ and Aman Sharma⁵, ¹Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Department of Nephrology,, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ³Internal Medicine, Junior Resident, Chandigarh, India, ⁴Histopathology, Professor, Chandigarh, India, ⁵Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: In addition to glomerular lesion, renal vascular lesion is also an important prognostic marker of lupus nephritis (LN). Among various vascular changes thrombotic microangiopathy…
Abstract Number: 2920 • 2015 ACR/ARHP Annual Meeting
Time to Recovery of Individual Lupus Manifestations on Standard of Care Treatment
Zahi Touma¹, Dafna Gladman¹, Jiandong Su¹ and Murray Urowitz^2,3, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Musculoskeletal, dermal and renal systems are the most commonly represented systems in lupus clinical trials. Thus, it is very important to study the time…
Abstract Number: 2921 • 2015 ACR/ARHP Annual Meeting
Lupus Nephritis: An Exploration of Management Style
Abhishek Nandan¹, Huzaefah Syed², Christen Vagts¹ and Jason Kidd¹, ¹Virginia Commonwealth University Medical Center, Richmond, VA, ²Rheumatology, Virginia Commonwealth University Medical Center, Richmond, VA
Background/Purpose: We aim to evaluate the differences and rationale behind the diagnostic and therapeutic approaches to proliferative lupus nephritis (LN) among nephrologists and rheumatologists. Methods:…
Abstract Number: 2922 • 2015 ACR/ARHP Annual Meeting
HLA-Specific Antibody Profile in Renal Transplant Patients with Systemic LUPUS Erythematosus
Diana Girnita¹, Paul Brailey² and Alin Girnita³, ¹Division of Immunology, Allergy & Rheumatology, University of Cincinnati Medical Center, Cincinnati, OH, ²Transplant Immunology Division, University of Cincinnati Medical Center -Hoxworth Blood Center, cincinnati, OH, Oman, ³Transplant Immunology Division, University of Cincinnati Academic Health Center, Hoxworth Blood Center, Cincinnati, OH
Background/Purpose: End stage renal disease due to Systemic lupus erytematosus (SLE) is one of the autoimmune disorder leading to renal transplantation. In this single-center study…
Abstract Number: 2923 • 2015 ACR/ARHP Annual Meeting
The Effects of Disease Activity and Mood Disorders on Cognitive Function in Systemic Lupus Erythematosus
Michelle Barraclough^1,2, Rebecca Elliott^2,3, Shane McKie^2,3, Ben Parker^1,2 and Ian N. Bruce^1,2, ¹Stopford Building, Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ²Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ³Stopford Building, Neuroscience and Psychiatry Unit, Institute of Brain and Behaviour and Mental Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Cognitive dysfunction (CD) significantly affects SLE patients with many contributing causal factors. The effect of disease activity on cognitive function remains unclear and currently…
Abstract Number: 2924 • 2015 ACR/ARHP Annual Meeting
Determinants of Damage in an SLE Cohort: Real World Data
Maria Francisca Moraes-Fontes¹, Eliana Silva², Nuno Riso³ and Margarida Jacinto⁴, ¹Autoimmune Diseases Unit, Serviço Medicina 7.2, Hospital de Curry Cabral, Centro Hospitalar Lisboa Central, Lisbon, Portugal, ²Patologia Clínica, Instituto Português de Oncologia, Francisco Gentil, Lisboa, Portugal, ³Serviço de Medicina 7.2, Hospital de Curry Cabral, Centro Hospitalar Lisboa Central, Lisbon, Portugal, ⁴Medicina Interna - Serviço 1, Hospital Espírito Santo - Évora, Évora, Portugal
Background/Purpose: Across the spectra of autoimmune diseases RA stands out, as biomarkers present from the onset are associated with severity and can be a guide…
Abstract Number: 2925 • 2015 ACR/ARHP Annual Meeting
Factors Associated with Early Damage Accrual in Patients with Systemic Lupus Erythematosus: 12-Month Preliminary Results from the Inception Cohort of the Multicenter Early Lupus Project
Matteo Piga¹, Fabiana Figus¹, Francesca Bellisai², Silvano Bettio³, Alessandra Bortoluzzi⁴, Laura Coladonato⁵, Fabrizio Conti⁶, Andrea Doria³, Mauro Galeazzi², Marcello Govoni⁴, Florenzo Iannone⁷, Annamaria Iuliano⁸, Marta Mosca⁹, Imma Prevete⁸, Gian Domenico Sebastiani⁸, Francesca Romana Spinelli¹⁰, Chiara Tani⁹ and Alessandro Mathieu¹, ¹University of Cagliari, Cagliari, Italy, ²University of Siena, Siena, Italy, ³Department of Medicine-DIMED, University of Padova, Padova, Italy, ⁴University of Ferrara, Ferrara, Italy, ⁵DIM, Rheumatology Unit, Bari, Italy, ⁶Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, ⁷Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy, ⁸Osp. San Camillo, Roma, Italy, ⁹University of Pisa, Pisa, Italy, ¹⁰Sapienza University of Rome, Rome, Italy
Background/Purpose: Preventing organ damage is a major challenge in management of Systemic Lupus Erythematosus (SLE). Few data are available on factors related to development of…
Abstract Number: 2926 • 2015 ACR/ARHP Annual Meeting
Cytochrome P450 Polymorphisms on Blood Hydroxychloroquine Levels in Patients with Systemic Lupus Erythematosus
Ji Yeon Lee¹, Min Kyung Chung², Ji Hun Kim², Jung Hee Koh³, Seung Min Jung⁴, Jennifer Lee², Seung-Ki Kwok⁵, Ji Hyeon Ju⁶, Kyung-Su Park⁷ and Sung-Hwan Park², ¹Division of Rheumatology, Department of Internal Medicine, School of Medicine, Catholic University of Korea, Seoul St. Mary’s Hospital, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, school of medicine, The catholic university of Korea, Seoul, South Korea, ⁵[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁷Division of Rheumatology, Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Hydroxychloroquine (HCQ) is a safe and effective treatment for systemic lupus erythematosus (SLE), and its blood concentration is known to be closely related to…
Abstract Number: 2927 • 2015 ACR/ARHP Annual Meeting
Disease Activity Patterns over Time in Patients with SLE – a Retrospective Descriptive Analysis of the Hopkins Lupus Cohort
Noémi Györi¹, Katerina Chatzidionysiou², Laurence S Magder³, Ronald F. van Vollenhoven¹ and Michelle Petri⁴, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Department of Medicine, Unit of Rheumatology, Department of Medicine Solna, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ³Johns Hopkins University School of Medicine, Devision of Rheumatology, Baltimore, MD, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multi-systemic inflammatory disease, characterized by an extreme variability of its expression, both between and within individuals, over time.…
Abstract Number: 2928 • 2015 ACR/ARHP Annual Meeting
Persistent Disease Activity over Time in a Large Canadian Cohort of Prevalent Lupus Patients
Christine A. Peschken¹, Willy Wynant², Michal Abrahamowicz³, Janet E. Pope⁴, Earl Silverman⁵, Amyn Sayani⁶, Sandra Iczkovitz⁶, Jorge A. Ross⁶, Christian Pineau⁷, C Douglas Smith⁸, Marie Hudson⁷, Michel Zummer⁹, Lori B. Tucker¹⁰, Deborah M. Levy¹¹, Gaëlle Chédeville¹², Adam M. Huber¹³, Hector Arbillaga¹⁴, Carol Hitchon¹⁵, Paul R. Fortin¹⁶ and CaNIOS 1000 Faces Investigators, ¹Arthritis Center, University of Manitoba, Winnipeg, MB, Canada, ²McGill University, Quebec, QC, Canada, ³Department of Epidemiology and Biostatistics., McGill University, Montreal, QC, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵Division of Rheumatology, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ⁶Medical Affairs, GlaxoSmithKline, Mississauga, ON, Canada, ⁷Medicine, McGill University, Montreal, QC, Canada, ⁸The Arthritis Centre, TOH Riverside Campus, Ottawa, ON, Canada, ⁹Rheumatology, Hôpital Maisonneuve-Rosemont and University of Montreal, Montreal, QC, Canada, ¹⁰Rheumatology, BC Children's Hospital, Vancouver, BC, Canada, ¹¹Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹²Rheumatology, McGill University, Montreal, QC, Canada, ¹³Pediatric rheumatology, IWK Health Centre, Halifax, NS, Canada, ¹⁴Calgary Rheumatology, Calgary, AB, Canada, ¹⁵University of Manitoba, Winnipeg, MB, Canada, ¹⁶Medicine, CHU de Québec - Université Laval, Québec, QC, Canada
Background/Purpose: Treatment of systemic lupus erythematosus (SLE) aims at controlling disease activity to prevent damage. In a large multi-centre cohort of prevalent SLE patients we…
Abstract Number: 2929 • 2015 ACR/ARHP Annual Meeting
Diet and Glucocorticoid Treatment in Patients with SLE
Cecilia Lourdudoss¹, Johan Frostegård² and Ronald F. van Vollenhoven³, ¹Dept. of Medicine, ClinTRID, Karolinska institutet, Stockholm, Sweden, ²Karolinska Institutet, Section of Immunology and chronic disease, Institute of Environmental Medicine, Stockholm, Sweden, ³Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden
Background/Purpose: Relatively little is known about the link between diet and treatment results in SLE. Glucocorticoids (GC) are used to control active SLE but minimized…
Abstract Number: 2930 • 2015 ACR/ARHP Annual Meeting
Outcome of Patients with Systemic Lupus Erythematous (SLE) after Thrombotic Events
Samar Alharbi¹, Jiandong Su², Stacey E. Morrison³, Mohammed Attar⁴, Khawla Al-Ghanim⁵, Murray Urowitz^6,7, Dafna Gladman² and Jorge Sánchez-Guerrero⁸, ¹Rheumatology, University Health Network, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Div Rheumatology Rm MP-10-304, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ⁵Rheumatology, TWH, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada
Background/Purpose: To assess the impact of thrombotic events (TE) on 1) mortality, 2) SLE-related damage accrual; and 3) health-related quality of life (HRQoL) in patients…
Abstract Number: 2931 • 2015 ACR/ARHP Annual Meeting
Is Pregnancy a Risk Factor for the Onset of Systemic Lupus Erythematosus (SLE) in Women of the Reproductive Age: A Population Based Case-Control Study?
Chi Chiu Mok¹, Sau Mei Tse¹, Ling Yin Ho² and Kar Li Chan¹, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong
Background/Purpose: To evaluate whether pregnancy is a risk factor for the onset of SLE in women of the reproductive age.Methods: Female patients who had first…
Abstract Number: 2932 • 2015 ACR/ARHP Annual Meeting
A Retrospective Observational Study of Patients with Lupus Nephritis Treated with Rituximab in Combination with Cyclophosphamide
Nídia Oliveira¹, Mónica Ibañez², Natalia Ciang³ and David A. Isenberg⁴, ¹Internal Medicine Department, Hospital Pedro Hispano, Matosinhos, Portugal, London, United Kingdom, ²Rheumatology Department, Hospital Son Llàtzer, Palma de Mallorca, Spain, London, United Kingdom, ³Rheumatology Department, Queen Eliazbeth Hospital, Hong Kong, London, United Kingdom, ⁴Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom
Background/Purpose: Lupus nephritis (LN) is a major cause of morbidity. Many patients with refractory disease can not tolerate conventional immunosuppressive therapy. The aims of this…
Abstract Number: 2933 • 2015 ACR/ARHP Annual Meeting
Low Prevalence of PCP in Hospitalized Patients with SLE: Review of a Clinical Database Warehouse
Teja Kapoor¹, Jianhua Li², Sameer Malhotra³, Joan Bathon⁴ and Anca Askanase⁵, ¹Columbia University, New York, NY, ²Columbia University Medical Center, New York, NY, ³Weill Cornell Medical Center, New York, NY, ⁴Rheumatology, Columbia University Medical Center, NY, NY, ⁵Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose : The risk of Pneumocystis carinii pneumonia (PCP) in Systemic Lupus Erythematosus (SLE) is not well-established. Accordingly, this study aims to establish the prevalence…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].